ICMJE DISCLOSURE FORM

Date:	2023.4.20		
Your Name	<u> </u>	Hong Hu	
Manuscrip	t Title:	Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update	∍ :
Preoperati	ve Immund	otherapy for triple-Negative Breast cancer	
Manuscrip	t number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	xNone	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	x None	
3	noyalties of ficelises	xivolie	
4	Consulting fees	xNone	

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	·		
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None		

Please place an "X" next to the following statement to indicate your agreement:

_x _I certify that I have answered every question and have not altered the wording of any of the questions on this

ICMJE DISCLOSURE FORM

Date:	2023.4.20	
Your Name		Virginia Kaklamani
Manuscript	Title:	Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: Preoperative
Immunothe	rapy for tr	iple-Negative Breast cancer
Manuscript	number (i	f known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	puma, lilly	

		astrazeneka	
		gilead,	
		tersera	
		daiichi,	
5	Payment or honoraria for	Pfizer	
	lectures, presentations,	gilead	
	speakers bureaus,	Genentech	
	manuscript writing or	genomic health	
	educational events	Novartis	
		astrazeneka	
		Daichi	
		seagen	
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	xNone	
	<i>G</i> ,		
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	xNone	
	·		
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

VK has received the consulting fees from puma, astrazeneka, gilead, tersera, daiichi, and lilly, and as the Speaker of Pfizer, gilead, Genentech, genomic health, Novartis, astrazeneka, Daichi, and seagen

Please place an "X" next to the following statement to indicate your agreement:
x _ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X